BRPI0912230A2 - Método para encapsular agentes biologicamente ativos em um carreador particulado, carreador particulado, e, composição farmacêutica - Google Patents

Método para encapsular agentes biologicamente ativos em um carreador particulado, carreador particulado, e, composição farmacêutica

Info

Publication number
BRPI0912230A2
BRPI0912230A2 BRPI0912230A BRPI0912230A BRPI0912230A2 BR PI0912230 A2 BRPI0912230 A2 BR PI0912230A2 BR PI0912230 A BRPI0912230 A BR PI0912230A BR PI0912230 A BRPI0912230 A BR PI0912230A BR PI0912230 A2 BRPI0912230 A2 BR PI0912230A2
Authority
BR
Brazil
Prior art keywords
particulate carrier
biologically active
active agents
encapsuling
pharmaceutical composition
Prior art date
Application number
BRPI0912230A
Other languages
English (en)
Inventor
Papanicolaou Irene
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0912230A2 publication Critical patent/BRPI0912230A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MÉTODO PARA ENCAPSULAR AGENTES BIOLOGICAMENTE ATIVOS EM UM CARREADOR PARTICULADO, CARREADOR PARTICULADO, E, COMPOSIÇÃO FARMACÊUTICA. A presente invenção fornece métodos de encapsular agentes biologicamente ativos tais como proteínas em carreadores particulados tais como nanopartículas usando-se agentes. Também são fornecidas composições que compreende carreadores particulados obteníveis por tais métodos e usos de tais composições no tratamento.
BRPI0912230A 2008-05-06 2009-05-05 Método para encapsular agentes biologicamente ativos em um carreador particulado, carreador particulado, e, composição farmacêutica BRPI0912230A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5077508P 2008-05-06 2008-05-06
US7417108P 2008-06-20 2008-06-20
PCT/EP2009/055438 WO2009135855A2 (en) 2008-05-06 2009-05-05 Encapsulation of biologically active agents

Publications (1)

Publication Number Publication Date
BRPI0912230A2 true BRPI0912230A2 (pt) 2017-08-22

Family

ID=43125562

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912230A BRPI0912230A2 (pt) 2008-05-06 2009-05-05 Método para encapsular agentes biologicamente ativos em um carreador particulado, carreador particulado, e, composição farmacêutica

Country Status (12)

Country Link
US (1) US20110059142A1 (pt)
EP (1) EP2273986A2 (pt)
JP (1) JP2011519894A (pt)
CN (1) CN102215830A (pt)
AU (1) AU2009245786A1 (pt)
BR (1) BRPI0912230A2 (pt)
CA (1) CA2721350A1 (pt)
EA (1) EA201001569A1 (pt)
IL (1) IL208655A0 (pt)
MX (1) MX2010012136A (pt)
WO (1) WO2009135855A2 (pt)
ZA (1) ZA201007436B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012137A (es) * 2008-05-06 2010-12-17 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos.
AU2014318566A1 (en) * 2013-09-12 2016-04-07 Thomas Jefferson University Novel delivery compositions and methods of using same
EP3116547B1 (en) * 2014-03-14 2019-06-05 Pfizer Inc Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
WO2015181344A1 (en) * 2014-05-30 2015-12-03 AbbVie Deutschland GmbH & Co. KG Nanoencapsulation of antigen-binding molecules
CN110478495A (zh) 2014-06-30 2019-11-22 塔弗达治疗有限公司 靶向缀合物及其颗粒和制剂
CN104771362B (zh) * 2014-09-03 2018-01-02 沈阳药科大学 一种克拉霉素离子对脂质微球注射液及其制备方法
CN108473538B (zh) 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂
MA44323A (fr) * 2015-11-20 2018-09-26 Abbvie Deutschland Nanosphères à surface modifiée encapsulant des molécules liant l'antigène
US11833486B2 (en) * 2015-11-29 2023-12-05 Berney PENG Functionalized nanoparticles having encapsulated guest cargo and methods for making the same
US11484505B2 (en) 2016-10-13 2022-11-01 Thomas Jefferson University Delivery compositions, and methods of making and using same
CN109260174B (zh) * 2018-09-04 2021-10-15 中山大学 一种治疗性蛋白纳米颗粒的高通量制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2649321A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
GB9300875D0 (en) * 1993-01-18 1993-03-10 Ucb Sa Nanocapsule containing pharmaceutical compositions
HUT74509A (en) * 1993-09-09 1997-01-28 Schering Ag Active principles and gas containing microparticles, their use for realising active principles in ultrasonically controlled manner, and process for preparing them
US20030152636A1 (en) * 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
JP2005514326A (ja) * 2001-07-10 2005-05-19 コリクサ コーポレイション ミクロスフェア中に封入されたタンパク質およびアジュバントを送達するための組成物および方法
AU2004259209A1 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions

Also Published As

Publication number Publication date
WO2009135855A2 (en) 2009-11-12
US20110059142A1 (en) 2011-03-10
AU2009245786A1 (en) 2009-11-12
EA201001569A1 (ru) 2011-10-31
MX2010012136A (es) 2010-12-17
EP2273986A2 (en) 2011-01-19
CN102215830A (zh) 2011-10-12
IL208655A0 (en) 2010-12-30
JP2011519894A (ja) 2011-07-14
CA2721350A1 (en) 2009-11-12
WO2009135855A3 (en) 2011-01-27
ZA201007436B (en) 2012-03-28

Similar Documents

Publication Publication Date Title
UY31809A (es) Encapsulación de agentes biológicamente activos
UA106631C2 (uk) Композиції з контрольованим вивільненням
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
BR112014005064A2 (pt) não solvatos de sal de norigobaína
BRPI1012141A2 (pt) conjugado de sirna e método de preparação do mesmo
BR112013018352A2 (pt) composição de minociclina tópica e método
BRPI0907591A2 (pt) Compostos e composição farmacêutica como moduladores de atividade de gpr119, método in vitro para modulação da atividade de gpr119 e usos do referido composto, seus sais farmaceuticamente aceitáveis ou suas composições farmacêuticas.
BR112013003101A2 (pt) inibidores do vírus da hepatite c
MX2012012668A (es) Aplicacion de alto cizallamiento en administracion de farmaco.
WO2009135855A3 (en) Encapsulation of biologically active agents
BRPI1014978A2 (pt) método de tratamento do câncer e composição farmacêutica.
EP2429987A4 (en) AMID COMPOUND, PHARMACEUTICAL METHOD AND PHARMACEUTICAL COMPOSITION THEREFOR
BR112014008616A2 (pt) compostos antivirais
BR112013024965A2 (pt) composto, composição farmacêutica, método de tratamento de infecções virais, e, processo para preparar um composto
UY33549A (es) Quinolil aminas como agentes inhibidores de las quinasas
PE20131065A1 (es) Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular
BR112013028679A2 (pt) inibidores do vírus da hepatite c
EP2292234A4 (en) COMPOSITIONS WITH CHINAZOLINE DERIVATIVES, METHOD OF MANUFACTURE AND THEIR USE
WO2012143679A3 (en) Coating composition for pathogen control in cotton
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
TR201907274T4 (tr) Kurutulmuş Biyoselüloz Üretimi İçin Yöntem.
AR075301A1 (es) Composicion y metodo para controlar enfermedades de plantas
EA201390646A1 (ru) Фармацевтические композиции
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN
EP2690088A4 (en) MIXED CRYSTAL AGOMELINATE OF FORM VIII, MANUFACTURING METHOD AND USE THEREOF, AND PHARMACEUTICAL COMPOSITION THEREWITH

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2435 DE 05-09-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 9/51 (2006.01), A61K 9/16 (2006.01), A61K 47/